Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial

Antonin Levy; David Azria; Jean Pierre Pignon; Anne Delarochefordiere; Isabelle Martel-Lafay; Emmanuel Rio; David Malka; Thierry Conroy; Laurent Miglianico; Yves Becouarn; Katty Malekzadeh; Julie Leclercq; Beata Juzyna; Patrick Ezra; Claire Lemanski; Eric Deutsch

doi:10.1016/j.radonc.2015.02.008

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial

Antonin Levy, David Azria, Jean Pierre Pignon, Anne Delarochefordiere, Isabelle Martel-Lafay, Emmanuel Rio, David Malka, Thierry Conroy, Laurent Miglianico, Yves Becouarn, Katty Malekzadeh, Julie Leclercq, Beata Juzyna, Patrick Ezra, Claire Lemanski, Eric Deutsch

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

31 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	415-416
Nombre de pages	2
journal	Radiotherapy and Oncology
Volume	114
Numéro de publication	3
Les DOIs	https://doi.org/10.1016/j.radonc.2015.02.008
état	Publié - 1 mars 2015

Accès au document

10.1016/j.radonc.2015.02.008

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Levy, A., Azria, D., Pignon, J. P., Delarochefordiere, A., Martel-Lafay, I., Rio, E., Malka, D., Conroy, T., Miglianico, L., Becouarn, Y., Malekzadeh, K., Leclercq, J., Juzyna, B., Ezra, P., Lemanski, C., & Deutsch, E. (2015). Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. Radiotherapy and Oncology, 114(3), 415-416. https://doi.org/10.1016/j.radonc.2015.02.008

@article{515c946b95bd4af5938a8fed8f02ba90,

title = "Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial",

author = "Antonin Levy and David Azria and Pignon, {Jean Pierre} and Anne Delarochefordiere and Isabelle Martel-Lafay and Emmanuel Rio and David Malka and Thierry Conroy and Laurent Miglianico and Yves Becouarn and Katty Malekzadeh and Julie Leclercq and Beata Juzyna and Patrick Ezra and Claire Lemanski and Eric Deutsch",

note = "Funding Information: This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.radonc.2015.02.008",

language = "English",

volume = "114",

pages = "415--416",

journal = "Radiotherapy and Oncology",

issn = "0167-8140",

number = "3",

}

Levy, A, Azria, D, Pignon, JP, Delarochefordiere, A, Martel-Lafay, I, Rio, E, Malka, D, Conroy, T, Miglianico, L, Becouarn, Y, Malekzadeh, K, Leclercq, J, Juzyna, B, Ezra, P, Lemanski, C & Deutsch, E 2015, 'Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial', Radiotherapy and Oncology, VOL. 114, Numéro 3, p. 415-416. https://doi.org/10.1016/j.radonc.2015.02.008

Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. / Levy, Antonin; Azria, David; Pignon, Jean Pierre et al.
Dans: Radiotherapy and Oncology, Vol 114, Numéro 3, 01.03.2015, p. 415-416.

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

TY - JOUR

T1 - Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer

T2 - Long-term results of the UNICANCER ACCORD 16 phase II trial

AU - Levy, Antonin

AU - Azria, David

AU - Pignon, Jean Pierre

AU - Delarochefordiere, Anne

AU - Martel-Lafay, Isabelle

AU - Rio, Emmanuel

AU - Malka, David

AU - Conroy, Thierry

AU - Miglianico, Laurent

AU - Becouarn, Yves

AU - Malekzadeh, Katty

AU - Leclercq, Julie

AU - Juzyna, Beata

AU - Ezra, Patrick

AU - Lemanski, Claire

AU - Deutsch, Eric

N1 - Funding Information: This study was funded by a medical Grant from Merck KGaA . Merck KGaA have reviewed this manuscript but the views and opinions described do not necessarily reflect those of Merck KGaA.

PY - 2015/3/1

Y1 - 2015/3/1

UR - http://www.scopus.com/inward/record.url?scp=84927571118&partnerID=8YFLogxK

U2 - 10.1016/j.radonc.2015.02.008

DO - 10.1016/j.radonc.2015.02.008

M3 - Letter

C2 - 25769380

AN - SCOPUS:84927571118

SN - 0167-8140

VL - 114

SP - 415

EP - 416

JO - Radiotherapy and Oncology

JF - Radiotherapy and Oncology

IS - 3

ER -